The FDA is taking a closer look at the safety of injectable drugs used to safeguard infants and toddlers from RSV, a common respiratory virus. But here's where it gets controversial: this review comes amidst a broader shift in childhood vaccination policies under Health Secretary Robert F. Kennedy Jr., who has been making waves with his decisions.
The drugs in question, produced by Merck and Sanofi, are not vaccines but provide protection against RSV. They are laboratory-created antibodies that mimic the body's natural immune response. While the FDA has approved vaccines for older patients and pregnant women, these injectables are the primary defense for young children against RSV. And this is the part most people miss: the review is not due to any new safety concerns, but rather a routine evaluation, according to a Kennedy spokesman.
Both drug manufacturers have expressed confidence in their products' safety profiles. Merck, maker of Enflonsia, welcomes FDA scrutiny, emphasizing transparency and rigorous review. Sanofi, on the other hand, has not identified any safety issues in over 50 studies involving its drug, Beyfortus, which has been administered to millions of babies worldwide.
RSV is usually a mild illness, but it can be severe for infants and the elderly. In 2023, CDC advisers recommended antibody shots for infants born during the RSV season if their mothers weren't vaccinated. This recommendation, along with others, has been subject to change under Kennedy's leadership, who has replaced the entire CDC committee.
The FDA's recent focus on vaccine safety, especially COVID-19 shots, has led to proposed reforms of its approval process. This raises questions: Is the FDA's review of these RSV drugs a routine measure or part of a larger shift in policy? How might these changes impact public health, especially for vulnerable populations? Share your thoughts below!
